Issue

Vol. 66 No. 5: Issue 5

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer

https://doi.org/10.14715/cmb/2020.66.5.35
Nan Chen
Department of Thoracic Surgery, Yunnan Tumor Hospital, Yunnan 650118, China
Gaofeng Li
Department of Thoracic Surgery, Yunnan Tumor Hospital, Yunnan 650118, China
Heng Li
Department of Thoracic Surgery, Yunnan Tumor Hospital, Yunnan 650118, China
Xudong Xiang
Department of Thoracic Surgery, Yunnan Tumor Hospital, Yunnan 650118, China
Gang Guo
Department of Thoracic Surgery, Yunnan Tumor Hospital, Yunnan 650118, China
Qianli Ma
Department of Thoracic Surgery, Yunnan Tumor Hospital, Yunnan 650118, China
Ying Zhang
Department of Radiology, Yunnan Tumor Hospital, Yunnan 650118, China

Corresponding Author(s) : Ying Zhang

chennande123@163.com

Cellular and Molecular Biology, Vol. 66 No. 5: Issue 5

Abstract

The purpose of this study was to investigate the potential of cell-free DNA (cfDNA) as a prognostic factor for non-small cell lung cancer (NSCLC).   Patients with NSCLC (n = 154) treated with gefitinib were recruited over a 5-year period for this study, and served as the observation group (79 males and 75 females, mean age = 53.74 ± 10.86 years). The control group (normal healthy individuals) consisted of 30 males and 22 females, aged 44 – 64 years (mean age = 54.12 ± 9.83 years). The follow-up lasted 5 years, or until the patient relapsed and died. The plasma level of cfDNA was determined in patients 1 day before treatment, 3 days after treatment, and on the 28th day of treatment.Based on the cfDNA expression level, NSCLC patients were subdivided into high-expression and low-expression groups, and differences in survival were compared. Univariate and multivariate analyses were performed on factors affecting patients survival using COX. Total effectiveness was significantly higher in observation group (49.35%) than in control group (13.95 %) (p<0.05). The extent of disease control wasalso significantly higher in the observation group (93.51 %) than in control group (p<0.05). Plasma cfDNA level of NSCLCpatients was significantly higher than that of control group before treatment, but was significantly and time-dependently reduced after gefitinib treatment (p<0.05). Cell-free DNA (cfDNA) level increased with severity of disease (p<0.05). Patients in cfDNA low-expression group had significantly higher chances of survival than those in the high-expression group (p<0.05). The results of Cox multivariate analysis showed that pathological severity and cfDNA concentration were independent factors affecting prognosis of NSCLC
(p<0.05). Plasma cfDNA is a potential prognostic index in patients with NSCLC.

Keywords

Cell-free DNA Gefitinib Lung cancer Prognosis Targeted therapy.
Chen, N., Li, G., Li, H., Xiang, X., Guo, G., Ma, Q., & Zhang, Y. (2020). Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer. Cellular and Molecular Biology, 66(5), 208–213. https://doi.org/10.14715/cmb/2020.66.5.35
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
  2. Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, et al. Analysis of the prevalence of malignant tumors in China in 2015. Chin J Oncol 2019; 41: 19-28.
  3. He J. Comprehensive treatment of operable non-small cell lung cancer. Chin J Oncol 2012; 34: 1-5.
  4. Xu JH, Wang XN, Huang X, Zhao L, Xu XM. Time analysis of drug resistance after first-line gefitinib treatment in advanced non-small cell lung cancer. Pract Pharm Clin Remedies 2020; 3: 224-229.
  5. Liu N, Zhang K, Yan SX, Jia XF, Chen WM, Zhang B, et al. EGFR mutations are closely associated with Gefitinib response in non-small cell lung cancer patients. J Mod Oncol 2013; 21: 330-333.
  6. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-437.
  7. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-1665.
  8. Chan LL, Jiang P. Bioinformatics analysis of circulating cell-free DNA sequencing data. Clin Biochem 2015; 48: 962-975.
  9. Chen H, Sun LY, Zheng HQ, Zhang QF, Jin XM. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. Pathol 2012; 44: 318-324.
  10. Fan QY, Wang YJ, Zhong YJ, Zhou ZF, Lu JW. Clinical significance of detection of plasma cfDNA in gastric cancer. Chin Clin Oncol 2020; 25: 241-245.
  11. Huang BL, Li XX, Wang L, Peng QX, Gu GH, Shi JF. Clinical significance of detection of plasma free DNA content and integrity in patients with non-small cell lung cancer. Chin J Clin Lab Sci 2015; 33: 602-605.
  12. Sun YF, Yang X, Fang C, Zhao WQ, Ji M. Significance of circulating tumor DNA in evaluating efficiency of non-small cell lung cancer. J Clin Med Pract 2018; 22: 49-52.
  13. Cui B. Effect of gefitinib on clinical treatment of advanced non-small cell lung cancer. Guide China Med 2020; 18: 56-57.
  14. Mo JH, Wang B, Lv YQ, Dong L. Research progress in circulating tumor DNA detection in early warning and monitoring management of non-small cell lung cancer. Int J Pathol Clin Med 2020; 40: 199-204.
  15. Song HH, Fu XH. Research Progress of Common Driver Genes and Corresponding Targeted Drugs in Non-small Cell Lung Cancer. Med Recapitulate 2020; 8: 1531-1536.
  16. Hu HL. Clinical Study of Gefitinib Combined with Simplified Intensity Modulated Radiotherapy in Treating Non-Small Cell Lung Cancer. China Pharm 2017; 26: 38-40.
  17. Wu ZF, Lin XX, Han JG. Efficacy and adverse reactions of gefitinib in the treatment of advanced non-small cell lung cancer. Chin J Clin Rational Drug Use 2020; 13: 45-46.
  18. Zhao J, Chen JY, Tang JC. Advances in the mechanism and treatment of gefitinib resistance in Non-small Cell Lung Cancer. Chin J Mod Appl Pharm 2017; 34: 923-927.
  19. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998; 17: 89-97.
  20. Fournié GJ, Courtin JP, Laval F, Chalé JJ, Pourrat JP, Pujazon MC, et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumors. Cancer Lett 1995; 91: 221-227.
  21. Jia DJ, Wang LJ, Cheng XF, Liu Y, Dai JL, Song J. Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer. Med Inf 2019; 32: 91-93.
  22. Wan NY. The value of serum cf-DNA quantitative detection in early diagnosis and prognosis of cervical cancer. Med Sci J Central South China 2018; 8: 365-367．
  23. Feng Y, Hu XS, Liu YT, Lin L, Xing PY, Hao XZ, et al. Analysis of efficacy, safety and survival of using apatinib in the treatment of 25 patients with advanced non-small cell lung cancer. Oncol Prog 2019; 17: 2268-2272．
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 755 Download : 417